- Report
- February 2023
- 220 Pages
Global
From €6657EUR$7,500USD£5,730GBP
- Report
- May 2024
- 140 Pages
Global
From €5769EUR$6,499USD£4,965GBP
- Report
- May 2024
- 137 Pages
Global
From €5769EUR$6,499USD£4,965GBP
- Report
- May 2024
- 136 Pages
Global
From €5769EUR$6,499USD£4,965GBP
- Report
- May 2024
- 130 Pages
Global
From €5769EUR$6,499USD£4,965GBP
- Report
- May 2024
- 139 Pages
Global
From €5769EUR$6,499USD£4,965GBP
- Report
- August 2024
- 80 Pages
Japan
From €3107EUR$3,500USD£2,674GBP
- Report
- August 2023
- 74 Pages
Canada
From €3107EUR$3,500USD£2,674GBP
- Report
- June 2024
- 200 Pages
Global
From €7057EUR$7,950USD£6,073GBP
- Report
- October 2022
- 210 Pages
Global
From €1775EUR$2,000USD£1,528GBP
- Report
- July 2023
- 108 Pages
Global
From €3500EUR$4,224USD£3,118GBP
- Report
- October 2022
- 63 Pages
Global
From €1775EUR$2,000USD£1,528GBP
Evolocumab is a monoclonal antibody used in the treatment of cardiovascular diseases. It is a PCSK9 inhibitor, which works by blocking the action of the PCSK9 protein, thus reducing the amount of low-density lipoprotein (LDL) cholesterol in the blood. This helps to reduce the risk of cardiovascular events such as heart attack and stroke. Evolocumab is administered as an injection, either subcutaneously or intravenously.
Evolocumab is used in combination with other lipid-lowering therapies, such as statins, to reduce LDL cholesterol levels in patients with primary hyperlipidemia or mixed dyslipidemia. It is also used in patients with homozygous familial hypercholesterolemia, who are unable to achieve adequate LDL cholesterol levels with other lipid-lowering therapies.
Evolocumab is marketed by several pharmaceutical companies, including Amgen, Sanofi, Regeneron, and Pfizer. It is also available as a generic drug in some countries. Show Less Read more